Association between uterine serous carcinoma and breast cancer

Gynecologic Oncology

Volumn 94, Issue 1, 2004, Pages 208-211

  Gehrig, Paola A ^a   Bae Jump, Victoria L ^a   Boggess, John F ^a   Groben, Pamela A ^a   Fowler Jr , Wesley C ^a   Van Le, Linda ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Endometrial cancer; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGE DISTRIBUTION; AGED; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; UTERUS CARCINOMA;

EID: 3242732352     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.04.009     Document Type: Article

References (17)

1. Cancer Facts and Figures 2004. American Cancer Society, Inc., Surveillance Research. 2004.
2. Cano A., Hermenegildo C. The endometrial effects of SERMs. Hum. Reprod. Update. 6:2000;244-254
3. Deligdisch L. Hormonal pathology of the endometrium. Mod. Pathol. 13:2000;285-294
4. Zhong M., Lu Z., Abbas T., Hornia A., Chatakondu K., Barile N., et al. Novel tumor-promoting property of Tamoxifen. Cell Growth Differ. 12:2001;187-192
5. Magriples U., Naftonlin F., Schwartz P.E., Carcangiu M.L. High grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin. Oncol. 11:1993;485-490
6. Barakat R.R., Wong G., Curtin J.P., Vlamix V., Hoskins W.J. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol. Oncol. 55:1994;164-168
7. Fisher B.M., Constantino J.P., Redmond C.K., Fisher E.R., Wickerman D.L., Cronin W.M., et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project B-14. J. Natl. Cancer Inst. 86:1994;527-537
8. Hendrickson M., Ross J., Eifel P., Martinez A., Kempson R. Uterine papillary serous carcinoma - A highly malignant form of endometrial adenocarcinoma. Am. J. Surg. Pathol. 6:1982;93-108
9. Geisler J.P., Sorosky J.L., Duong H.L., Buekers T.E., Geisler J.M., Sood A.K., et al. Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast cancer. Gynecol. Oncol. 83:2001;501-503
10. Moslehi R., Chu W., Karlan B., Rishman D., Risch H., Fields A., et al. BRCA1 and BRCA2 analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am. J. Hum. Genet. 66:2000;1259-1272
11. Aziz S., Kuperstein G., Rosen B., Mclaughlin J., Narod S.A. A genetic epidemiological study of fallopian tube carcinoma. Gynecol. Oncol. 80:2001;341-345
12. Bandera C.A., Muto M.G., Schorge J.O., Berkowitz R.S., Rubin S.C., Mok S.C. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet. Gynecol. 92:1998;596-600
13. Lavie O., Hornreich G., Ben Arie A., Renbaum P., Levy-Lahad E., Beller U. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet. Gynecol. 96:2000;28-32
14. Hornreich G., Beller U., Lavie O., Renbaum P., Cohen Y., Levy-Lahad E. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol. Oncol. 75:1999;300-304
15. Goshen R., Chu W., Elit L., Pal T., Hakimi J., Ackerman I., et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol. Oncol. 79:2000;477-481
16. Lavie O., Hornreich G., Ben-Arie A., Renart G., Renbaum P., Levy-Lehad E., et al. BRCA1/2 germline mutations in women with uterine serous papillary carcinoma. Gynecol. Oncol. 88:2003;194
17. Gehrig P.A., Groben P.A., Fowler W.C., Walton L.A., Van Le L. Noninvasive papillary serous carcinoma of the endometrium. Obstet. Gynecol. 97:2001;153-157